Content without topic

Hypocholesterolemia friend or foe?
Stefano Romeo, Arca Marcello, Mathilde Di-Filippo, Luca Valenti
September 20, 2022 | Webinars on-demand
How does diabetes accelerate atherosclerosis?
Karin Bornfeldt
May 25, 2022 | Young fellows’ session, 90th EAS Congress 2022
Macrophage metabolism in atherosclerosis
Laurent Yvan-Charvet
May 25, 2022 | Young fellows’ session, 90th EAS Congress 2022
Atherosclerosis-associated chronic inflammation: the outcome of metabolic imbalances or irregular immune responses?
Chrysoula Boutari
May 25, 2022 | Young fellows’ session, 90th EAS Congress 2022
How does endothelial rewiring contribute to ASCVD?
Jeffrey Kroon
May 25, 2022 | Young fellows’ session, 90th EAS Congress 2022
Clonal hematopoiesis affecting cardiovascular health
José J. Fuster
May 25, 2022 | Aging and dementia and stroke, 90th EAS Congress 2022
Debate session – HDL: In search for a function – Discussion and Q&A
Giuseppe Danilo Norata, Stefano Romeo, Arnold von Eckardstein, Anne Tybjaerg-Hansen
May 25, 2022 | Debate session - HDL: In search for a function, 90th EAS Congress 2022
HDL: In search for a function – Anne Tybjærg-Hansen
Anne Tybjaerg-Hansen
May 25, 2022 | Debate session - HDL: In search for a function, 90th EAS Congress 2022
HDL: In search for a function – Arnold von Eckardstein
Arnold von Eckardstein
May 25, 2022 | Debate session - HDL: In search for a function, 90th EAS Congress 2022
Aging, dementia and stroke – Discussion and Q&A
Alexandros Tselepis, Ruth Frikke-Schmidt, José J. Fuster, Martin Bennett, Hasanga Manikpurage, Kévin Chemello, Dianne van Dam-Nolen, Olivier Mansier, Liv Nordestgaard
May 25, 2022 | Aging and dementia and stroke, 90th EAS Congress 2022
Body mass index and risk of dementia
Liv Nordestgaard
May 25, 2022 | Aging and dementia and stroke, 90th EAS Congress 2022
Carotid plaque characteristics predict recurrent ischemic stroke: the plaque at risk (parisk) study
Dianne van Dam-Nolen
May 25, 2022 | Aging and dementia and stroke, 90th EAS Congress 2022
Clonal hematopoiesis are not associated with an increased systemic inflammation, atherosclerosis nor incidence of atherothrombosis : results from the 3-city study (chip-3c)
Olivier Mansier
May 25, 2022 | Aging and dementia and stroke, 90th EAS Congress 2022
Combining polygenic risk scores to predict myocardial infarction in the canadian longitudinal study on aging
Hasanga Manikpurage
May 25, 2022 | Aging and dementia and stroke, 90th EAS Congress 2022
Lipoprotein(A) is a residual cardiovascular risk factor in statin treated stroke survivors: insights from the sparcl trial
Kévin Chemello
May 25, 2022 | Aging and dementia and stroke, 90th EAS Congress 2022
Cell senescence in atherosclerosis and vascular ageing
Martin Bennett
May 25, 2022 | Aging and dementia and stroke, 90th EAS Congress 2022
Imaging guided management – Discussion and Q&A
Ulf Landmesser, Oner Ozdogan, Michael Blaha, Steve Nicholls, Antonio Gallo, Veronika Myasoedova, Horea-Laurentiu Onea, Reindert Oostveen, Paolo Raggi
May 25, 2022 | Imaging guided management, 90th EAS Congress 2022
Non-alcoholic to metabolic associated fatty liver disease: cardiovascular implications of a change in terminology in patients living with HIV
Paolo Raggi
May 25, 2022 | Imaging guided management, 90th EAS Congress 2022
Statin treatment dampens arterial wall inflammation assessed with 68GA-dotatate PET/CT
Reindert Oostveen
May 25, 2022 | Imaging guided management, 90th EAS Congress 2022
OCT imaging of a wide spectrum of culprit plaque morphology features in acute coronary syndromes
Horea-Laurentiu Onea
May 25, 2022 | Imaging guided management, 90th EAS Congress 2022
Aortic valve sclerosis in acute myocardial infarction patients and its association with long-term mortality
Veronika Myasoedova
May 25, 2022 | Imaging guided management, 90th EAS Congress 2022
Non-calcific atherosclerotic burden in hefh: the FH-calc study.
Antonio Gallo
May 25, 2022 | Imaging guided management, 90th EAS Congress 2022
Imaging for plaque progression
Steve Nicholls
May 25, 2022 | Imaging guided management, 90th EAS Congress 2022
Imaging guided prevention: Hype or real?
Michael Blaha
May 25, 2022 | Imaging guided management, 90th EAS Congress 2022
New World of targeted therapies (targets, delivery systems,new molecules) – Discussion and Q&A
Franco Bernini, Nathan Wong, Sekar Kathiresan, Megan Levings, Hana Totary-Jain, Alexis Hofherr, Laura D'Erasmo
May 25, 2022 | New World of targeted therapies (targets and delivery systems and new molecules), 90th EAS Congress 2022
Lomitapide in the long-term real-world management of HOFH – effectiveness, tolerability, and hepatic safety data from the pan-european study
Laura D'Erasmo
May 25, 2022 | New World of targeted therapies (targets and delivery systems and new molecules), 90th EAS Congress 2022
Etesian: a phase 2B study of the efficacy, safety and tolerability of AZD8233, a PCSK9-targeted antisense oligonucleotide, in patients with dyslipidemia
Alexis Hofherr
May 25, 2022 | New World of targeted therapies (targets and delivery systems and new molecules), 90th EAS Congress 2022
Novel anti-atherosclerotic MRNA-based therapy
Hana Totary-Jain
May 25, 2022 | New World of targeted therapies (targets and delivery systems and new molecules), 90th EAS Congress 2022
Cell based therapies in atherosclerosis
Megan Levings
May 25, 2022 | New World of targeted therapies (targets and delivery systems and new molecules), 90th EAS Congress 2022
Developing medicines that mimic resistance mutations
Sekar Kathiresan
May 25, 2022 | New World of targeted therapies (targets and delivery systems and new molecules), 90th EAS Congress 2022
Targeting non-coding RNAs
Kathryn Moore
May 25, 2022 | 90th EAS Congress 2022, Plenary 3: From lifestyle to designer therapies
NLA/EAS joint session – Primordial prevention: The neglected topic – Discussion and Q&A
Joseph Saseen, Kausik Ray, Lale Tokgözoğlu, Kevin Maki, Mai-Lis Hellenius, Anne Carol Goldberg
May 24, 2022 | NLA/EAS joint session - Primordial prevention: The neglected topic, 90th EAS Congress 2022
Premordial prevention – How to make it work?
Anne Carol Goldberg
May 24, 2022 | NLA/EAS joint session - Primordial prevention: The neglected topic, 90th EAS Congress 2022
Physical activity end cardiovascular prevention
Mai-Lis Hellenius
May 24, 2022 | NLA/EAS joint session - Primordial prevention: The neglected topic, 90th EAS Congress 2022
What is the optimal diet to prevent ASCVD?
Kevin Maki
May 24, 2022 | NLA/EAS joint session - Primordial prevention: The neglected topic, 90th EAS Congress 2022
Why do we need primordial prevention?
Lale Tokgözoğlu
May 24, 2022 | NLA/EAS joint session - Primordial prevention: The neglected topic, 90th EAS Congress 2022
IME Session – Should public health recommendations target Lp(a) measurements? – Discussion and Q&A
Alberico L. Catapano, Borge Nordestgaard, Elisabeth Steinhagen-Thiessen
May 24, 2022 | IME Session - Should public health recommendations target Lp(a) measurements?, 90th EAS Congress 2022
The patient with high Lp(a)
Elisabeth Steinhagen-Thiessen
May 24, 2022 | IME Session - Should public health recommendations target Lp(a) measurements?, 90th EAS Congress 2022
Lp(a) a causal risk factor for cardiovascular disease
Borge Nordestgaard
May 24, 2022 | IME Session - Should public health recommendations target Lp(a) measurements?, 90th EAS Congress 2022
Understanding 3D culture in smooth muscle cell biology and the modelling of atherosclerosis
Mei Shan Ong
May 24, 2022 | Smooth muscle cell biology and plaque stability, 90th EAS Congress 2022
The epigenetic enzyme DOT1L orchestrates VSMC–monocyte crosstalk to protect against atherosclerosis via the NF-KB pathway
Floriana Farina
May 24, 2022 | Smooth muscle cell biology and plaque stability, 90th EAS Congress 2022
Smooth muscle cell-specific deletion of S100A4 reroutes smooth muscle cell fate and modifies the inflammatory status of murine atherosclerotic lesions
Luis Cardoso dos Santos
May 24, 2022 | Smooth muscle cell biology and plaque stability, 90th EAS Congress 2022
Lamin A/C expression in hematopoietic cells regulates mouse atherosclerosis: a potential mechanism contributing to age-dependent atherosclerosis
Marta Amorós-Pérez
May 24, 2022 | Smooth muscle cell biology and plaque stability, 90th EAS Congress 2022
Gasdermin D deficiency delays atherogenesis but stimulates plaque apoptosis in apoe-/- mice
Pauline Puylaert
May 24, 2022 | Smooth muscle cell biology and plaque stability, 90th EAS Congress 2022
Smooth muscle cells plasticity in plaque stability
Marie-Luce Bochaton-Piallat
May 24, 2022 | Smooth muscle cell biology and plaque stability, 90th EAS Congress 2022
The role of necroptosis in atherogenesis and plaque stability
Katey Rayner
May 24, 2022 | Smooth muscle cell biology and plaque stability, 90th EAS Congress 2022
Liver specific targeting of ANGPTL4 using a galnac conjugated antisense oligonucleotides approach
Stefan Nilsson
May 24, 2022 |
Cholestyramine perinatal treatment of apoe deficient mice reduces atherosclerotic plaques development in adult offspring
Marina Habib
May 24, 2022 | Late breaker session 2, 90th EAS Congress 2022
Epigenetics regulate gene expression of metalloprotease-9 and tissue inhibitor of metalloprotease type 2 in acute coronary syndrome
Bruno Baudin
May 24, 2022 | Late breaker session 2, 90th EAS Congress 2022
A pi3kciialpha/primary cilium-dependent autophagy program protects endothelial cells in response to atheroprone shear stress
Muriel Laffargue
May 24, 2022 | Late breaker session 2, 90th EAS Congress 2022
Silencing of ANGPTL4 via antisense oligonucleotides effectively reduces plasma triglyceride and glucose levels in mice without causing lymphadenopathy
Stefan Nilsson
May 24, 2022 | Late breaker session 2, 90th EAS Congress 2022
Antagonism of MIR-148A attenuates the progression of atherosclerosis in apobtgapobec-/-LDLR+/- mice
Noemi Rotllan
May 24, 2022 | Late breaker session 2, 90th EAS Congress 2022
Estimating the magnitude of LDL-C reduction needed to overcome the increased risk of atherosclerotic cardiovascular events caused by LP(A) to guide clinical management
Brian Ference
May 24, 2022 | Late breaker session 2, 90th EAS Congress 2022
Lipoprotein(A) does not have a clinically significant arterial or venous prothrombotic effect
Elena Olmastroni
May 24, 2022 | Late breaker session 2, 90th EAS Congress 2022
Cell metabolism in endothelial cells
Michael Potente
May 24, 2022 | 90th EAS Congress 2022, Endothelial cell biology in atherosclerosis
Apo B containing lipoproteins – Discussion and Q&A
Arca Marcello, Katariina Öörni, Marina Cuchel, Bart van de Sluis, Willemien van Zwol, Ilenia Minicocci, Manuela Casula, Zivile Girkantaite, Camilla Johannesen
May 24, 2022 | 90th EAS Congress 2022, Apo B containing lipoproteins
Importance of APOB and non-HDL cholesterol for ischemic stroke is double that of LDL cholesterol
Camilla Johannesen
May 24, 2022 | 90th EAS Congress 2022, Apo B containing lipoproteins
Do triglycerides have an influence on endothelial function detected by laser doppler flowmetry?
Zivile Girkantaite
May 24, 2022 | 90th EAS Congress 2022, Apo B containing lipoproteins
LDL-cholesterol levels and LDL polygenic score in a cohort of patients with clinically diagnosed familial hypercholesterolemia. Data from the lipigen study
Manuela Casula
May 24, 2022 | FH Week 2022, 90th EAS Congress 2022, Apo B containing lipoproteins
The genetic lack of ANGTPL3 does not alter HDL functionality
Ilenia Minicocci
May 24, 2022 | 90th EAS Congress 2022, Apo B containing lipoproteins
Hepatic SMLR1 ablation fully protects against diet-induced atherosclerosis but causes hepatosteatosis via reduced VLDL secretion
Willemien van Zwol
May 24, 2022 | 90th EAS Congress 2022, Apo B containing lipoproteins
Intracellular regulation of lipoprotein receptors
Bart van de Sluis
May 24, 2022 | 90th EAS Congress 2022, Apo B containing lipoproteins
LDL disposal: Receptor vs non-receptor
Marina Cuchel
May 24, 2022 | 90th EAS Congress 2022, Apo B containing lipoproteins
Lp(a): The next frontier
Sotirios Tsimikas
May 24, 2022 | 90th EAS Congress 2022, Plenary 2: Lipoproteins revisited: What has changed ?
Emerging therapies for dyslipidemia
Daniel Gaudet
May 24, 2022 | 90th EAS Congress 2022, Plenary 2: Lipoproteins revisited: What has changed ?
ApoB – friend and foe
Jan Kuivenhoven
May 24, 2022 | 90th EAS Congress 2022, Plenary 2: Lipoproteins revisited: What has changed ?
Trigylcerides: From systemic to cellular metabolism
Ira Goldberg
May 24, 2022 | 90th EAS Congress 2022, Plenary 2: Lipoproteins revisited: What has changed ?
Industrial Breakfast Session – Disussion and Q&A
Michal Vrablik, Matthew Willcox, Ingo Hilgendorf
May 23, 2022 | Industry Breakfast Session, 90th EAS Congress 2022
Managing LDL-C through a practical lens: A case study
Ingo Hilgendorf
May 23, 2022 | Industry Breakfast Session, 90th EAS Congress 2022
Managing LDL-C through a behavioral lens – Matthew Willcox
Matthew Willcox
May 23, 2022 | Industry Breakfast Session, 90th EAS Congress 2022
Managing LDL-C through a clinician’s lens – Michal Vrablík
Michal Vrablik
May 23, 2022 | Industry Breakfast Session, 90th EAS Congress 2022
Industry Special Lecture – Discussion and Q&A
Alberico L. Catapano, Florian Kronenberg, Elisabeth Steinhagen-Thiessen
May 23, 2022 | Industry Special Lecture, 90th EAS Congress 2022
Elevated Lp(a) in clinical practice – Implications for managing our patients
Elisabeth Steinhagen-Thiessen
May 23, 2022 | Industry Special Lecture, 90th EAS Congress 2022
Why measure Lp(a) and how do I interpret it?
Florian Kronenberg
May 23, 2022 | Industry Special Lecture, 90th EAS Congress 2022
Lp(a): What we need to know
Alberico L. Catapano
May 23, 2022 | Industry Special Lecture, 90th EAS Congress 2022
Reductions in VLDL and Remnant Cholesterol through inhibition of ANGPTL3 Protein Synthesis: An Analysis from TRANSLATE-TIMI 70
Nicholas Marston
May 23, 2022 | 90th EAS Congress 2022, Late breaker session 1
Granzyme B+ CD4+ T cells associate with an unstable plaque phenotype in advanced human atherosclerosis
Marie Depuydt
May 23, 2022 | 90th EAS Congress 2022, Modulating immune responses in atherosclerosis
Identification of CD8+ T cell PRDM1 in high-risk human plaques and its regulatory role in murine lesion development
Sanne Maas
May 23, 2022 | 90th EAS Congress 2022, Modulating immune responses in atherosclerosis
Immunumometabolic role of sterol element binding protein 1C (SREBP1C) in tregulatory cell function
Fabrizia Bonacina
May 23, 2022 | 90th EAS Congress 2022, Modulating immune responses in atherosclerosis
JMJD3-deficiency in CD4+ T cells attenuates atherosclerosis by modulating T-cell polarization
Cecilia Bonfiglio
May 23, 2022 | 90th EAS Congress 2022, Modulating immune responses in atherosclerosis
Deletion of viperin in the hematopoietic system aggravates atherosclerosis
Dimitrios Tsiantoulas
May 23, 2022 | 90th EAS Congress 2022, Modulating immune responses in atherosclerosis
Modulating T cell immunity in ASCVD
Ziad Mallat
May 23, 2022 | 90th EAS Congress 2022, Modulating immune responses in atherosclerosis
Macrophage plasticity in atherosclerotic plaques
Claudia Monaco
May 23, 2022 | 90th EAS Congress 2022, Modulating immune responses in atherosclerosis
Why and how to implement early combination lipid lowering therapy – Discussion and Q&A
Maciej Banach, Lale Tokgözoğlu, Carlos Escobar Cervantes, Kausik Ray
May 23, 2022 | 90th EAS Congress 2022, Why and how to implement early combination lipid lowering therapy
An App to guide clinical care – what is it and how should we use it
Kausik Ray
May 23, 2022 | 90th EAS Congress 2022, Why and how to implement early combination lipid lowering therapy
How to implement decision algorithms into routine clinical care- experience across Europe
Carlos Escobar Cervantes
May 23, 2022 | 90th EAS Congress 2022, Why and how to implement early combination lipid lowering therapy
Pragmatic strategies to better implement combination therapies for very high risk patients
Maciej Banach
May 23, 2022 | 90th EAS Congress 2022, Why and how to implement early combination lipid lowering therapy
How can we optimise lipid lowering after acute coronary syndromes?
Lale Tokgözoğlu
May 23, 2022 | 90th EAS Congress 2022, Why and how to implement early combination lipid lowering therapy
Non-classical risk factors: Transitioning from association to causality – Discussion and Q&A
Christoph Binder, Giulia Chiesa, Felix Jansen, Manuel Mayr, Peter Thomas, Florian Mourre, Julia Ramírez, Sabine Bauer, Hyung Joon Joo
May 23, 2022 | 90th EAS Congress 2022, Non-classical risk factors: Transitioning from association to causality
Comparison of cardiovascular prognosis between triglyceride variability and exposure estimate in diabetic patients
Hyung Joon Joo
May 23, 2022 | 90th EAS Congress 2022, Non-classical risk factors: Transitioning from association to causality
Vascular tissue specific mirna profiles reveal novel correlations with risk factors in coronary artery disease
Sabine Bauer
May 23, 2022 | 90th EAS Congress 2022, Non-classical risk factors: Transitioning from association to causality
Prediction of coronary artery disease and major adverse cardiovascular events using clinical and genetic risk scores for cardiovascular risk factors
Julia Ramírez
May 23, 2022 | 90th EAS Congress 2022, Non-classical risk factors: Transitioning from association to causality
Maternal inheritance of a genetic mutation for familial hypercholesterolemia predispose to coronary atherosclerosis in adulthood
Florian Mourre
May 23, 2022 | FH Week 2022, 90th EAS Congress 2022, Non-classical risk factors: Transitioning from association to causality
High lipoprotein(a) and systemic inflammation jointly confer additive high risk of atherosclerotic cardiovascular disease and aortic valve stenosis
Peter Thomas
May 23, 2022 | 90th EAS Congress 2022, Non-classical risk factors: Transitioning from association to causality
Systems biology to estimate cardiovascular risk
Manuel Mayr
May 23, 2022 | 90th EAS Congress 2022, Non-classical risk factors: Transitioning from association to causality
Extracellular vesicles in CVD
Felix Jansen
May 23, 2022 | 90th EAS Congress 2022, Non-classical risk factors: Transitioning from association to causality
High blood neutrophil counts and ischemic vascular disease: observational and genetic studies
Jiao Luo
May 23, 2022 | 90th EAS Congress 2022, Late breaker session 1
High cholesterol absorption is associated with increased cardiovascular risk in hemodialysis patients: insights from the aurora study
Günther Silbernagel
May 23, 2022 | 90th EAS Congress 2022, Late breaker session 1
Effect of genetic susceptibility to common human disorders on plasma lipidome
Rubina Tabassum
May 23, 2022 | 90th EAS Congress 2022, Late breaker session 1
Global perspective of paediatric familial hypercholesterolaemia: analysis from the EAS FHSC registry on over 11,200 children and adolescents with heterozygous familial hypercholesterolaemia from 44 countries
Kanika Dharmayat
May 23, 2022 | FH Week 2022, 90th EAS Congress 2022, Late breaker session 1
Genome-wide association study on HDL-mediated cholesterol efflux capacity
Johanna Schachtl-Riess
May 23, 2022 | 90th EAS Congress 2022, Late breaker session 1
A first-in-human single ascending dose study of a monoclonal antibody against the ANGPTL3/8 complex in subjects with mixed hyperlipidemia
Daniel Gaudet
May 23, 2022 | 90th EAS Congress 2022, Late breaker session 1
Obicetrapib lowers LDL-C in patients on high intensity statins results from the rose trial (nct04753606)
Kausik Ray
May 23, 2022 | 90th EAS Congress 2022, Late breaker session 1
HOFH: new insights in therapeutic approaches – Discussion and Q&A
Philippe Moulin, Frederick Raal, Daniel Gaudet, Arca Marcello
May 23, 2022 | FH Week 2022, 90th EAS Congress 2022, HOFH: new insights in therapeutic approaches
Introduction and case study
Frederick Raal
May 23, 2022 | 90th EAS Congress 2022, HOFH: new insights in therapeutic approaches
Novel therapeutic options
Daniel Gaudet
May 23, 2022 | 90th EAS Congress 2022, HOFH: new insights in therapeutic approaches
HoFH: where do we stand?
Arca Marcello
May 23, 2022 | FH Week 2022, 90th EAS Congress 2022, HOFH: new insights in therapeutic approaches
Is the risk of atherosclerotic cardiovascular disease different between genotype determined or measured LP(a) levels?
Frederica Galimberti
May 23, 2022 | 90th EAS Congress 2022, Free Communication 1 - Genetics of Dyslipidemia
Comparison of different LDL-C genetic risk score in a sample of clinical FH patients
Ana Medeiros
May 23, 2022 | FH Week 2022, 90th EAS Congress 2022, Free Communication 1 - Genetics of Dyslipidemia
Universal screening is an effective strategy for detecting patients with familial hypercholesterolemia
Urša Šuštar
May 23, 2022 | FH Week 2022, 90th EAS Congress 2022, Free Communication 1 - Genetics of Dyslipidemia
Modelling a two-stage screen for autosomal dominant familial hypercholesterolaemia (FH) in UK biobank
Jasmine Gratton
May 23, 2022 | FH Week 2022, 90th EAS Congress 2022, Free Communication 1 - Genetics of Dyslipidemia
Immune-inflammatory proteomics associated with elevated cardiovascular risk in genetically determined familial hypercholesterolemia
Andrea Baragetti
May 23, 2022 | FH Week 2022, 90th EAS Congress 2022, Free Communication 1 - Genetics of Dyslipidemia
Lysosomal acid lipase (LAL) deficiency alters immune cells distribution in mice and humans
Rossella Bellini
May 23, 2022 | 90th EAS Congress 2022, Free Communication 1 - Genetics of Dyslipidemia
Environment and cardiovascular risk – Discussion and Q&A
Dan Gaita, Jeanine Roeters van Lennep, Patrick Schrauwen, Thomas Münzel, Tess Yntema, David Burgner, Karsten Grote
May 23, 2022 | 90th EAS Congress 2022, Environment and cardiovascular risk
Microplastic particles induce endothelial activation
Karsten Grote
May 23, 2022 | 90th EAS Congress 2022, Environment and cardiovascular risk
Early life infection is associated with proinflammatory, atherogenic, and diabetogenic metabolomic and lipidomic profiles at 12 months of age
David Burgner
May 23, 2022 | 90th EAS Congress 2022, Environment and cardiovascular risk
Western-type diet overrules the protective effect of commensal bacteria in atherogenesis
Tess Yntema
May 23, 2022 | 90th EAS Congress 2022, Environment and cardiovascular risk
Environment
Thomas Münzel
May 23, 2022 | 90th EAS Congress 2022, Environment and cardiovascular risk
Exercise and cardiovascular disease in 2022: When, who and how ?
Patrick Schrauwen
May 23, 2022 | 90th EAS Congress 2022, Environment and cardiovascular risk
Dietary components and patterns as determinants of cardiovascular risk
Alice Lichtenstein
May 23, 2022 | 90th EAS Congress 2022, Environment and cardiovascular risk
Lipoprotein(a) and SARS-COV-2 infections: risk for ischemic heart disease and thromboembolic events
Silvia Di Maio
May 23, 2022 | 90th EAS Congress 2022, Atherothrombosis and myeloid cells
In vivo detection of urokinase-type plasminogen activator receptor (UPAR) expression in arterial atherogenesis using [64CU]CU-DOTA-AE105 positron emission tomography
Harshvardhan Khare
May 23, 2022 | 90th EAS Congress 2022, Atherothrombosis and myeloid cells
TP53-mutant clonal hematopoiesis accelerates experimental atherosclerosis development
Nuria Matesanz
May 23, 2022 | 90th EAS Congress 2022, Atherothrombosis and myeloid cells
Detailing the role of neutrophils in atherothrombosis
Irene Lang
May 23, 2022 | 90th EAS Congress 2022, Atherothrombosis and myeloid cells
Platelet activation and inhibition in atherothrombosis and inflammation
Carlo Patrono
May 23, 2022 | 90th EAS Congress 2022, Atherothrombosis and myeloid cells
The human gut microbiome and personalized nutrition
Nicola Segata
May 23, 2022 | 90th EAS Congress 2022, Targeting risk factors with lifestyle
Carbohydrate/fat or caloric restriction on glycaemia and lipids pathways – what do the trials tell us?
Nicola Guess
May 23, 2022 | 90th EAS Congress 2022, Targeting risk factors with lifestyle
Can exercise be tailored to address specific risk factors?
Michael Papadakis
May 23, 2022 | 90th EAS Congress 2022, Targeting risk factors with lifestyle
Efficacy of a novel PCSK9 inhibitory peptide alone and in combination with an anti-ANGPTL3 monoclonal antibody in a mouse model of atherosclerosis
Bidda Rolin
May 23, 2022 | 90th EAS Congress 2022, PCSK9 – new insights
Proprotein convertase subtilisin/kexin type 9 (PCSK9) modulates cholesterol homeostasis and neuroinflammation in cell models of astrocytes and neurons
Bianca Papotti
May 23, 2022 | 90th EAS Congress 2022, PCSK9 – new insights
PCSK9 modulates cardiac metabolism and impacts HFPEF
Lorenzo Da Dalt
May 23, 2022 | 90th EAS Congress 2022, PCSK9 – new insights
Deciphering PCSK9 function in the intestine
Bertrand Cariou
May 23, 2022 | 90th EAS Congress 2022, PCSK9 – new insights
The role of PCSK9 in glucose metabolism and cardiac biology
Giuseppe Danilo Norata
May 23, 2022 | 90th EAS Congress 2022, PCSK9 – new insights
IAS/EAS joint session – What is the environment doing to our health? – Discussion and Q&A
Raul Santos, Stefano Romeo, Sanjay Rajagopalan, Thomas Münzel, Khurram Nasir, Ruth Loos
May 23, 2022 | 90th EAS Congress 2022, IAS/EAS joint session - What is the environment doing to our health?
Gene environment interaction
Ruth Loos
May 23, 2022 | 90th EAS Congress 2022, IAS/EAS joint session - What is the environment doing to our health?
Social Vulnerability and Cardiovascular Disease
Khurram Nasir
May 23, 2022 | 90th EAS Congress 2022, IAS/EAS joint session - What is the environment doing to our health?
Air pollution, City Design and Cardiovascular Disease
Thomas Münzel
May 23, 2022 | 90th EAS Congress 2022, IAS/EAS joint session - What is the environment doing to our health?
Heart healthy cities
Sanjay Rajagopalan
May 23, 2022 | 90th EAS Congress 2022, IAS/EAS joint session - What is the environment doing to our health?
WHF Session 1: WHF Roadmap on Cholesterol update – Discussion and Q&A
Kausik Ray, Raul Santos, Fernando Lanas Zanetti, Brian Ference
May 23, 2022 | 90th EAS Congress 2022, WHF Session 1: WHF Roadmap on Cholesterol update
Cumulative exposure, estimating benefits of early invention of lifetime risk
Brian Ference
May 23, 2022 | 90th EAS Congress 2022, WHF Session 1: WHF Roadmap on Cholesterol update
Translating science into policy
Fernando Lanas Zanetti
May 23, 2022 | 90th EAS Congress 2022, WHF Session 1: WHF Roadmap on Cholesterol update
Implementation today’s key concepts
Raul Santos
May 23, 2022 | 90th EAS Congress 2022, WHF Session 1: WHF Roadmap on Cholesterol update
Overall Concept
Kausik Ray
May 23, 2022 | 90th EAS Congress 2022, WHF Session 1: WHF Roadmap on Cholesterol update
Stratified treatment of ACS
Filippo Crea
May 23, 2022 | 90th EAS Congress 2022, Keynote Lecture
Debate: Who needs injectable therapies for cholesterol lowering? Statins and ezetimibe are enough for CVD prevention – Discussion and Q&A
Alberico L. Catapano, Ian Graham, Brian Ference, Ulrich Laufs, Michal Vrablik
May 23, 2022 | 90th EAS Congress 2022, ESC/EAS joint session: A deep dive into Prevention GLs with focus on dyslipidemia
How to implement this personalised approach?
Michal Vrablik
May 23, 2022 | 90th EAS Congress 2022, ESC/EAS joint session: A deep dive into Prevention GLs with focus on dyslipidemia
What is new in secondary prevention?
Ulrich Laufs
May 23, 2022 | 90th EAS Congress 2022, ESC/EAS joint session: A deep dive into Prevention GLs with focus on dyslipidemia
What is new in prevention in apparently healthy persons?
Brian Ference
May 23, 2022 | 90th EAS Congress 2022, ESC/EAS joint session: A deep dive into Prevention GLs with focus on dyslipidemia
Advances in risk estimation
Ian Graham
May 23, 2022 | ESC/EAS joint session: A deep dive into Prevention GLs with focus on dyslipidemia
Implementing genetics scores in clinical practice
Amit V. Khera
May 23, 2022 | 90th EAS Congress 2022, Plenary 1: Personalised approach to ASVD: The future is here
Imaging and biomarkers: Targeting the right patient for the right treatment
Wolfgang Koenig
May 23, 2022 | 90th EAS Congress 2022, Plenary 1: Personalised approach to ASVD: The future is here
Vascular response in atherosclerosis: From epigenetics to bone marrow
Eicke Latz
May 23, 2022 | 90th EAS Congress 2022, Plenary 1: Personalised approach to ASVD: The future is here
Deep phenotyping of disease
Chiara Giannarelli
May 23, 2022 | 90th EAS Congress 2022, Plenary 1: Personalised approach to ASVD: The future is here
The Anitschkow Lecture
Borge Nordestgaard
May 22, 2022 | 90th EAS Congress 2022, Opening Ceremony incl. Anitschkow Lecture
Reimagining population health-the time is now – Discussion and Q&A
Erik Stroes, Marianne Benn, Brian Ference, Lale Tokgözoğlu, Kausik Ray
May 22, 2022 | Reimagining population health-the time is now, 90th EAS Congress 2022
Reimagining prevention: the population approach
Kausik Ray
May 22, 2022 | Reimagining population health-the time is now, 90th EAS Congress 2022
Reimagining imaging to guide intensity of treatment – who what and how?
Lale Tokgözoğlu
May 22, 2022 | Reimagining population health-the time is now, 90th EAS Congress 2022
Reimagining prevention – Using AI and causal estimates to preserve health?
Brian Ference
May 22, 2022 | Reimagining population health-the time is now, 90th EAS Congress 2022
Omega 3 fatty acids in cardiovascular prevention – Where do we stand? – Discussion and Q&A
Alberico L. Catapano, Gabriel Steg, Aldo Pietro Maggioni, Preston Mason
May 22, 2022 | 90th EAS Congress 2022, Omega 3 fatty acids in cardiovascular prevention - Where do we stand?
Recent trials with Omega 3, lessons to be learned
Gabriel Steg
May 22, 2022 | 90th EAS Congress 2022, Omega 3 fatty acids in cardiovascular prevention - Where do we stand?
Are omega 3 made all equal?
Preston Mason
May 22, 2022 | 90th EAS Congress 2022, Omega 3 fatty acids in cardiovascular prevention - Where do we stand?
The Omega 3 story from nutrition to pharmacology
Aldo Pietro Maggioni
May 22, 2022 | 90th EAS Congress 2022, Omega 3 fatty acids in cardiovascular prevention - Where do we stand?
Implementation of the 2019 lipid guidelines-where are we now? – Discussion and Q&A
Alberico L. Catapano, Maurizio Averna, Kausik Ray, Heinz Drexel, Luis Masana, Francois Mach
May 22, 2022 | 90th EAS Congress 2022, Implementation of the 2019 lipid guidelines-where are we now?
Slow and sure wins the race- a stepwise approach
Francois Mach
May 22, 2022 | 90th EAS Congress 2022, Implementation of the 2019 lipid guidelines-where are we now?
Start with combination therapy and get on with it
Luis Masana
May 22, 2022 | 90th EAS Congress 2022, Implementation of the 2019 lipid guidelines-where are we now?
Using novel therapies in the real world- case studies
Heinz Drexel
May 22, 2022 | 90th EAS Congress 2022, Implementation of the 2019 lipid guidelines-where are we now?
What’s been achieved and what more is needed – real world evidence
Kausik Ray
May 22, 2022 | 90th EAS Congress 2022, Implementation of the 2019 lipid guidelines-where are we now?
Diabetes, Obesity and Atherosclerosis – New Horizons in ASCVD Prevention – Discussion and Q&A
Lale Tokgözoğlu, Kausik Ray, Frederick Raal, Mansoor Husain
May 22, 2022 | 90th EAS Congress 2022, Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention
Does targeting incretin pathways impact cardiovascular outcomes
Frederick Raal
May 22, 2022 | 90th EAS Congress 2022, Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention
Incretin and related pathways and their role in atherosclerosis
Mansoor Husain
May 22, 2022 | 90th EAS Congress 2022, Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention
The epidemiology of DM and obesity and risk of ASCVD
Kausik Ray
May 22, 2022 | 90th EAS Congress 2022, Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention
Prevention and Treatment of Atherosclerosis – Improving State-of-the-Art Management and Search for Novel Targets
January 1, 2022 | Publications, Handbook
How infraclinic atherosclerosis assessment contributes to personalized lipidology
Eric Bruckert, Stephan Gielen, Sara Boccalini, Philippe Moulin
Webinars on-demand
Aligning plasma lipidomics and metabolic studies in lipid metabolism
Jan Borén, Peter Würtz, Gerald Watts, Marianne Benn
Webinars on-demand
Open Lecture Nov 2021: Gene-based therapies – The next generation of Atherosclerosis treatment
Rosanne M. Crooke, Kees Hovingh
Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease European Atherosclerosis Society/European Society of Vascular Medicine Joint Statement
November 8, 2021 | Consensus paper, Publications
From genomics to gene expression in cardiovascular disease
Kári Stefánsson, Minna Kaikkonen-Määttä, Ruth Loos, Christoph Binder
Webinars on-demand
Women, dyslipidaemia and atherosclerosis
Lale Tokgözoğlu, Fabrice Bonnet, Erin D. Michos, Jeanine Roeters van Lennep
Webinars on-demand
Fatty Liver and Cardiovascular Disease: Partners in Crime?
Christopher D Byrne, Stefano Romeo, Luca Valenti, Olov Wiklund
Webinars on-demand
Lipids and atherosclerosis in COVID era
Giuseppina Caligiuri, Alberto Corsini, Handrean Soran, Lale Tokgözoğlu
Webinars on-demand
Understanding lipoprotein(a) in cardiovascular disease
Pia Rørbæk Kamstrup, Alexandros Tselepis, Massimiliano Ruscica, Stefano Romeo
October 27, 2021 | Webinars on-demand
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
September 30, 2021 | Guideline, Publications
Weight reduction and atherosclerotic benefits ; from actual evidence to future challenges
Luc van Gaal
89th EAS Congress 2021
Impaired resolution of inflammation – role of lipid mediators
Magnus Back
89th EAS Congress 2021
Humoral immune responses in the artery wall.
Christoph Binder
89th EAS Congress 2021
How to optimize CVD risk reduction
Francesco Cosentino
89th EAS Congress 2021
How to optimize atherothromobotic therapies to reduce CVD risk
Riitta Lassila
89th EAS Congress 2021
HoFH – can we move away from apheresis
Frederick Raal
FH Week 2022, 89th EAS Congress 2021
Gender and Cardiovascular Disease
DeLisa Fairweather
89th EAS Congress 2021
Gender specific risks in women
Jeanine Roeters van Lennep
89th EAS Congress 2021
From risk factors to acute coronary syndrome in women
Lale Tokgözoğlu
89th EAS Congress 2021
Fibrates to date – a bridge too far
Henry Ginsberg
89th EAS Congress 2021
Exercise inactivity and circadian rhythms – re-setting the clock in metabolic disease
Juleen Zierath
89th EAS Congress 2021
Evolving Concepts- Moving from PPAR to SPARM
Bart Staels
89th EAS Congress 2021
Dietary polyphenols and arterial stiffness
Guido De Meyer
89th EAS Congress 2021
Coronary Artery Calcification and its Progression: What Does it Really Mean?
Renu Virmani
89th EAS Congress 2021
Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
September 7, 2021 | Publications
Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society
September 2, 2021 | Consensus paper, Publications
The new guidelines for dyslipidaemia
Heinz Drexel
Intro to Clinical Lipidology
The clinical experience
Maciej Banach
Intro to Clinical Lipidology
Ongoing studies
Ulrich Laufs
Intro to Clinical Lipidology
Mendelian randomization
Brian Ference
Intro to Clinical Lipidology
CV disease risk classification
Lale Tokgözoğlu
Intro to Clinical Lipidology
Current available therapies – Statins
Jan Borén
Intro to Clinical Lipidology
Current available therapies – PCSK9 inhibition
Ulrich Laufs
Intro to Clinical Lipidology
Current available therapies – Omega3 & fibrates
Maciej Banach
Intro to Clinical Lipidology
Current available therapies – Ezetimbe
Alberico L. Catapano
Intro to Clinical Lipidology
Course presentations – An Introduction to Clinical Lipidology, October 2019
Lale Tokgözoğlu
Intro to Clinical Lipidology
Bempedoic acid – Mechanism of action
Alberico L. Catapano
Intro to Clinical Lipidology
The role of Dendritic Cells in Atherosclerosis
Clement Cochain
EAS AC VII
T cell subsets in atherosclerosis
Maria Wigren
EAS AC VII
Ontogeny and atherosclerosis pathology of B lymphocytes
Stephen Malin
EAS AC VII
Immunomodulation of atherosclerosis
Daniel F.J. Ketelhuth
EAS AC VII
Exploration and modulation of regulatory T cells in atherosclerosis
Hafid Ait-Oufella
EAS AC VII
Emerging cardiovascular therapies targeting the immune system
Jan Nilsson
EAS AC VII
Circulating Cells and Cardiovascular Risk
Harry Björkbacka
EAS AC VII
The role of new lipid lowering drugs
Kausik Ray
EAS AC on FH
The population burden of FH- The need to close the gap
Kausik Ray
EAS AC on FH
The lipid clinic and organization of FH, the role of different participants in the team
Kjetil Retterstøl
EAS AC on FH
Swedish experience from patient society
Gunnar Karlsson
EAS AC on FH
Genetics of FH mutation and distribution
Stefano Romeo
EAS AC on FH
Diagnosis of FH – Scoring systems and Genetic diagnosis, Polygenic causes of clinical FH
Joep Defesche
EAS AC on FH
Cascade screening introduction and experience from Spain
Pedro Mata
EAS AC on FH
Cascade screening introduction and experience from Czech Republic
Tomas Freiberger
EAS AC on FH
What have Mendelian Randomization studies revealed for cardiovascular disease beyond lipids?
Marianne Benn
EAS AC on Epidemiology & Genetics
Using genetics to predict drug effects and adverse events
Anne Tybjaerg-Hansen
EAS AC on Epidemiology & Genetics
The case of lipoprotein(a) and cardiovascular disease
Pia Rørbæk Kamstrup
EAS AC on Epidemiology & Genetics
The case for triglyceride-rich lipoproteins and cardiovascular disease
Borge Nordestgaard
EAS AC on Epidemiology & Genetics
New and old lipid-lowering drugs
Lale Tokgözoğlu
EAS AC on Epidemiology & Genetics
Global burden of cardiovascular disease and contribution of risk factors
Gregory Roth
EAS AC on Epidemiology & Genetics
Genetic disorders of lipid metabolism – with special focus on familial hypercholesterolaemia
Kees Hovingh
EAS AC on Epidemiology & Genetics
Concepts of Mendelian randomization
Shah Ebrahim
EAS AC on Epidemiology & Genetics
Causality of lipid traits for other diseases
Ruth Frikke-Schmidt
EAS AC on Epidemiology & Genetics
Biology of lipid metabolism
Patrick Rensen
EAS AC on Epidemiology & Genetics
2016 ESC-EAS guidelines for the management of dyslipidaemias-risk prediction and treatments targets
Olov Wiklund
EAS AC on Epidemiology & Genetics
Regulation of lipid metabolism by inflammation
Laurent Yvan-Charvet
EAS AC on Dyslipidaemia & Inflammation
LDL retention
Jan Borén
EAS AC on Dyslipidaemia & Inflammation
Innate immunity – Inflammasome
Eicke Latz
EAS AC on Dyslipidaemia & Inflammation
Adaptive Immunity – T cells and B cells
Ziad Mallat
EAS AC on Dyslipidaemia & Inflammation
Plasma lipoproteins and their role in atherogenesis
Jan Borén
EAS AC in Lipidology
PCSK9 inhibitor therapy – The cure for atherosclerosis?
Frederick Raal
EAS AC in Lipidology
PCSK9 Inhibition – HIGHLIGHTS FROM RECENT PUBLICATIONS
Alberico L. Catapano
EAS AC in Lipidology
PCSK9 – From promise to clinical practice
Gilles Lambert
EAS AC in Lipidology
Panel discussion
Faculty Presenter(s)
EAS AC in Lipidology
Lipid lowering therapies – statins
Steve Nicholls
EAS AC in Lipidology
Lipid guidelines, where we stand?
Alberico L. Catapano
EAS AC in Lipidology
Introduction to the course
Alberico L. Catapano
EAS AC in Lipidology
HDL, non HDL cholesterol and TG – a role in atherosclerosis?
Kausik Ray
EAS AC in Lipidology
Genetics for the identification of therapeutic targets in dyslipidaemia
Brian Ference
EAS AC in Lipidology
Familial hypercholesterolemia detection and treatment and the EAS Initiatives
Kausik Ray
EAS AC in Lipidology
Epidemiology of dyslipidemias focus on the region
Hung-I Yeh
EAS AC in Lipidology
CVD – Epidemiology of the risk factors – the central role of LDL cholesterol
Lale Tokgözoğlu
EAS AC in Lipidology
Combination Therapy with non-Statin lipid lowering therapies
Steve Nicholls
EAS AC in Lipidology
Closing remarks
Alberico L. Catapano
EAS AC in Lipidology
Clinical Cases Discussion
Faculty Presenter(s)
EAS AC in Lipidology
Will precision medicine help tailor dyslipidemia treatment?
Alberto Zambon
EAS 2017 AC on Precision Medicine in A
Precision Cardiovascular Medicine – an unmet need or just a fashion?
Eran Leitersdorf
EAS 2017 AC on Precision Medicine in A
Nutrigenomics for prevention and treatment of obesity
Judith Aron-Wisnewsky
EAS 2017 AC on Precision Medicine in A
Is there a role for Advanced Atherosclerosis Imaging in targeted cardiovascular therapy?
Erik Stroes
EAS 2017 AC on Precision Medicine in A
Identification of novel targets in Hypertension and priorities for drug development
David Rosenbaum
EAS 2017 AC on Precision Medicine in A
Human Genetics from validation of novel cardiovascular drug targets to molecular diagnosis
Alain Carrié
EAS 2017 AC on Precision Medicine in A
Do Novel Biomarkers improve cardiovascular risk stratification?
Arnold von Eckardstein
EAS 2017 AC on Precision Medicine in A
Can we refine strategy on HDL by new pharmacological approaches?
John Chapman
EAS 2017 AC on Precision Medicine in A
Venous vs. arterial thrombosis
Cihan Ay
EAS 2017 AC on Atherothrombosis
Tissue Factor
Nigel Mackman
EAS 2017 AC on Atherothrombosis
Systemsbiology and cardiovascular disease
Jörg Menche
EAS 2017 AC on Atherothrombosis
Platelets and the vascular wall
Rory Koenen
EAS 2017 AC on Atherothrombosis
Monocytes and atherothrombosis
Johann Wojta
EAS 2017 AC on Atherothrombosis
Mechanisms of plaque rupture and erosion
Gerard Pasterkamp
EAS 2017 AC on Atherothrombosis
Immunothrombosis
Steffen Massberg
EAS 2017 AC on Atherothrombosis
Humoral immunity and thrombosis
Christoph Binder
EAS 2017 AC on Atherothrombosis
Gut microbiome and atherothrombosis
Christoph Reinhardt
EAS 2017 AC on Atherothrombosis
Clotting factors and atherothrombosis
Hugo Ten Cate
EAS 2017 AC on Atherothrombosis
Clinical aspects of atherothrombosis
Irene Lang
EAS 2017 AC on Atherothrombosis
Antiphospholipid antibodies and thrombosis
Karl Lackner
EAS 2017 AC on Atherothrombosis
Recent evidence for the prevention of atherosclerotic cardiovascular diseases
Petri Kovanen
Basic science perspectives
Lipoprotein Metabolism
Arnold von Eckardstein
Basic science perspectives
Treatment of FH – Diet, statin and statin intolerance
Olov Wiklund
An introduction to FH for clinicians
FH in children
Albert Wiegman
An introduction to FH for clinicians
An introduction to Familial Hypercholesterolaemia for clinicians
Stefano Romeo
An introduction to FH for clinicians
Training Agenda Overview
Alberico L. Catapano
An Introduction to Clinical Lipidology
The new guidelines for dyslipidaemia
Alberico L. Catapano
An Introduction to Clinical Lipidology
Statins, including intolerance
Lale Tokgözoğlu
An Introduction to Clinical Lipidology
PCSK9 Inhibition including Inclisiran
Ulf Landmesser
An Introduction to Clinical Lipidology
Omega 3 and fibrates
Jan Borén
An Introduction to Clinical Lipidology
Management of dyslipidaemic patients in clinical practice
Lale Tokgözoğlu
An Introduction to Clinical Lipidology
Lipoprotein metabolism and the causal role of LDL in atherosclerosis
Jan Borén
An Introduction to Clinical Lipidology
Guidelines – the goals why?
Alberico L. Catapano
An Introduction to Clinical Lipidology
Guidelines – FH patients
Jan Borén
An Introduction to Clinical Lipidology
Guidelines – Diabetic patients
Brian Ference
An Introduction to Clinical Lipidology
Guidelines – Diabetic patients
Heinz Drexel
An Introduction to Clinical Lipidology
Guidelines – ACS & very highrisk patients
Ulrich Laufs
An Introduction to Clinical Lipidology
Guidelines – ACS & very high risk patients
Lale Tokgözoğlu
An Introduction to Clinical Lipidology
Ezetimibe
Heinz Drexel
An Introduction to Clinical Lipidology
EAS Introduction
Lale Tokgözoğlu
An Introduction to Clinical Lipidology
CV disease risk classification
Lale Tokgözoğlu
An Introduction to Clinical Lipidology
Bempedoic Acid – The clinical experience
Ulf Landmesser
An Introduction to Clinical Lipidology
Bempedoic Acid – Mechanism of action
Alberico L. Catapano
An Introduction to Clinical Lipidology
What is the landscape on lipid management today?
Lale Tokgözoğlu
88th EAS Congress 2020
What is the environment doing to cardiovascular health?
Nicole Probst-Hensch
88th EAS Congress 2020
What do we know so far about bempedoic acid?
Kausik Ray
88th EAS Congress 2020
Translating science into guidance on the prevention of cardiovascular disease
Guy De Baker
88th EAS Congress 2020
The value of omega 3 – from biology to clinical practice
Alberto Zambon
88th EAS Congress 2020
The lipoprotein(a) story – from risk factor to causality to clinical trials
Sotirios Tsimikas
88th EAS Congress 2020
The biology of PCSK9
Bertrand Cariou
88th EAS Congress 2020
The Angiopoietin-like proteins, controlling lipoprotein metabolism
Sander Kersten
88th EAS Congress 2020
TG-rich lipoproteins as a risk factor
Ruth Frikke-Schmidt
88th EAS Congress 2020
siRNA based approaches targeting hepatic synthesis of PCSK9
Kausik Ray
88th EAS Congress 2020
Risk stratification in very high risk patients is it of value?
Faculty Presenter(s)
88th EAS Congress 2020
Prevention of cardiovascular diseases by glucose lowering drugs
Stefano Del Prato
88th EAS Congress 2020
Position of omega 3 in Guidelines (as second choice after statins)
Christie Ballantyne
88th EAS Congress 2020
New therapeutic approaches
John J. Kastelein
88th EAS Congress 2020
Monoclonal antibody approaches targeting circulating PCSK9
Ulf Landmesser
88th EAS Congress 2020
Implementing systems biology to personalise medicine
Johan Björkegren
88th EAS Congress 2020
Immune modulation in atherosclerosis
Ziad Mallat
88th EAS Congress 2020
Global perspectives of cardiovascular disease, and impact of risk factors
Gregory Roth
88th EAS Congress 2020
Difficult cases to reach goal – Recurrent event on statin
Michel Farnier
88th EAS Congress 2020
Difficult cases to reach goal – FH
Meral Kayikcioglu
88th EAS Congress 2020
Case – Diabetic patient with MI – how to manage?
Dirk Muller-Wieland
88th EAS Congress 2020
Can polygenic scores reach clinical practice?
Anne Tybjaerg-Hansen
88th EAS Congress 2020
Can combination aid adherence ? (fixed dose, intolerance)
Michal Vrablik
88th EAS Congress 2020
Are the new EAS-ESC lipids goals reachable in clinical practice?
Francois Mach
88th EAS Congress 2020
Anitschkow Lecture – The Oxidation Hypothesis of Atherosclerosis Revisited – A Pivotal Role of OxPL in Atherosclerosis, NASH and Inflammation
Joseph L. Witztum
88th EAS Congress 2020
An update on the results of ODYSSEY outcomes
Gabriel Steg
88th EAS Congress 2020
AI in CVD & beyond
Jörg Menche
88th EAS Congress 2020
Behaviour change in CVD prevention
Heinke Englert
88th EAS Congress 2020
Precision nutrition and CVD management
Jogchum Plat
88th EAS Congress 2020
What is the price to pay if we are not at goal?
Alberto Zambon
87th EAS Congress 2019
What is the evidence for upfront combination?
Michel Farnier
87th EAS Congress 2019
The metabolic basis of FCS
Stefano Romeo
87th EAS Congress 2019
The immune system – The next game-changer?
Matthias Nahrendorf
87th EAS Congress 2019
The HDL story – Time to reconsider?
John Chapman
87th EAS Congress 2019
The genetic evidence for inhibiting the cholesterol synthesis pathway to control LDL cholesterol
Brian Ference
87th EAS Congress 2019
The genetic burden in CVD
Heribert Schunkert
87th EAS Congress 2019
The criticality of LDL goal attainment
Maciej Banach
87th EAS Congress 2019
System-Level analyses of inflammatory and repair Macrophages reveal an integrated circuitry of lipid and epigenomic changes
Laszlo Nagy
87th EAS Congress 2019
Risk Prediction for Add on Lipid Modulating Therapy
Kausik Ray
87th EAS Congress 2019
Reduce-It – An in depth analysis
Christie Ballantyne
87th EAS Congress 2019
Reality check – Can we get to Guideline recommended targets?
Kornelia Kotseva
87th EAS Congress 2019
Possibilities for Nutrigenetics and Nutraceuticals in CVD prevention
Jogchum Plat
87th EAS Congress 2019
Physician-Patient relationship – Challenges and opportunities
Lale Tokgözoğlu
87th EAS Congress 2019
Pharmacology of Bempedoic acid
Giuseppe Danilo Norata
87th EAS Congress 2019
PCSK9 inhibition in clinical practice
Francois Mach
87th EAS Congress 2019
Optimising cholesterol lowering treatment – How many times do we learn the same lesson?
Luis Masana
87th EAS Congress 2019
Optimal lipid lowering therapy – New and established therapies
Christie Ballantyne
87th EAS Congress 2019
Omega 3 fatty acids – Biological functions
Alexandros Tselepis
87th EAS Congress 2019
Omega 3 and CV benefit a review of the clinical trials
Aldo Pietro Maggioni
87th EAS Congress 2019
New lipid drugs – Is LDL done, ready for new targets?
Erik Stroes
87th EAS Congress 2019
Modified lipids and lipoproteins
Joseph L. Witztum
87th EAS Congress 2019
Microbiome – A New Theory of Atherosclerosis?
Thomas Luscher
87th EAS Congress 2019
Lipolysis of triglyceride-rich lipoproteins, vascular inflammation, and atherosclerosis
Jan Borén
87th EAS Congress 2019
Inflammation, Inhibition and Atherothrombosis
Paul Ridker
87th EAS Congress 2019
How good are we in reaching the goals?
Guy De Baker
87th EAS Congress 2019
Estimating risk – What’s new?
Ian Graham
87th EAS Congress 2019
Efficacy and safety of nutraceuticals
Maciej Banach
87th EAS Congress 2019
Different approaches to LDL lowering – An overview of options including nutrition, food supplements, and drug therapy
John Chapman
87th EAS Congress 2019
Current evidence for LDL causality; Goals and targets
Chris Packard
87th EAS Congress 2019
Complex cases in lipid lowering treatment – One simple high intensity cholesterol lowering approach fits them all
Arman Postadzhiyan
87th EAS Congress 2019
Clinical experience with Bempedoic Acid
Christie Ballantyne
87th EAS Congress 2019
Cardiovascular aging and Mitochondia function
Douglas Seals
87th EAS Congress 2019
Biomarkers predicting CVD
Chris Packard
87th EAS Congress 2019
A Journey From Plaque to Pate
Helen Hobbs
87th EAS Congress 2019
A deep look to the results of Odyssey outcomes
J. Wouter Jukema
87th EAS Congress 2019
Will inhibiting thrombus formation prevent acute coronary syndromes?
Stephan Gielen
86th EAS Congress 2018
Will aggressive LDL reduction prevent atherosclerosis?
Alberico L. Catapano
86th EAS Congress 2018
Why does the diet rich in unsaturated fat protect against cardiovascular disease? Differences between nuts and extra virgin olive oil
Emilio Ros
86th EAS Congress 2018
The role of bile acids in cholesterol homeostasis
Albert K. Groen
86th EAS Congress 2018
The multifaceted aspects of CV prevention – from nutrition to therapy – Chair
Alberico L. Catapano, Alberto Mello e Silva, Xavier Pinto
86th EAS Congress 2018
The ideal patient for PCSK9
J. Wouter Jukema
86th EAS Congress 2018
The Anitschkow Lecture – Genetics of cardiovascular disease – from ugly duckling to beautiful swan
Anne Tybjaerg-Hansen
86th EAS Congress 2018
Stress, behavior and cardiovascular disease
Viola Vaccarino
86th EAS Congress 2018
Strategies to treat vulnerable plaques
David Erlinge
86th EAS Congress 2018
Silencing genes, new targets
Sotirios Tsimikas
86th EAS Congress 2018
Shifting concepts in the description of the vulnerable plaque
Gerard Pasterkamp
86th EAS Congress 2018
Science versus reality in long term management – Time for a paradigm shift?
Lale Tokgözoğlu
86th EAS Congress 2018
RNA editing controls atherosclerosis
Stephanie Dimmeler
86th EAS Congress 2018
Reducing cholesterol by dietary means
Eric Bruckert
86th EAS Congress 2018
Reality check – Can we get to goals in guidelines?
Ulrich Laufs
86th EAS Congress 2018
PCSK9 inhibition the clinical evidence
Peter Sever
86th EAS Congress 2018
PCSK9 Inhibition in high risk patients
Gabriel Steg
86th EAS Congress 2018
Patient journey after acute coronary syndromes – can we improve outcomes? – Chair
Peter Toth
86th EAS Congress 2018
Panel Discussion
Faculty Presenter(s)
86th EAS Congress 2018
Optimising therapy through cardiac rehabilitation
Anselm Gitt
86th EAS Congress 2018
Novel therapeutic approaches using antisense inhibition
Joseph L. Witztum
86th EAS Congress 2018
Novel role of a Triglyceride-synthesizing enzyme – DGAT1 at the crossroad between Triglyceride and cholesterol metabolism
Vinay Sachdev
86th EAS Congress 2018
New targets for controlling dyslipidaemias and atherosclerosis – chair
Paolo Parini
86th EAS Congress 2018
Neoatherosclerosis from a pathologist’s point of view
Renu Virmani
86th EAS Congress 2018
Nanomedicine as novel atherosclerosis therapy
Willem J.M Mulder
86th EAS Congress 2018
Molecular and biochemical mechanisms involved in the protective effect of Mediterranean diet against atherosclerosis
Alvaro Hernaez
86th EAS Congress 2018
Mining the blood for new cardiometabolic markers
Robert Gerszten
86th EAS Congress 2018
Lipids, inflammation and CV risk
Erik Stroes
86th EAS Congress 2018
Lipid Signaling pathways in physiology and disease
Peter Tontonoz
86th EAS Congress 2018
Lessons from genetics – risk-score and novel candidates
Brian Ference
86th EAS Congress 2018
Lessons from epidemiology and environmental CVD risk factors
Salim Yusuf
86th EAS Congress 2018
LDL and apoB-lipoprotein as causative agents in ASCVD
Chris Packard
86th EAS Congress 2018
Keynote Lecture – Chair
Petri Kovanen
86th EAS Congress 2018
Is there need to revise goals from lipid lowering?
Ulf Landmesser
86th EAS Congress 2018
Incremental value of established therapies for dyslipidaemic patients
Luis Masana
86th EAS Congress 2018
Imaging and CVD risk estimation (population studies)
Valentin Fuster
86th EAS Congress 2018
How to control atherogenic dyslipidaemia
Henry Ginsberg
86th EAS Congress 2018
Hospital management after acute coronary syndromes – Is the risk over ?
Jose L Zamorano
86th EAS Congress 2018
High-resolution lipoprotein phenotypes and cardiovascular outcomes
Samia Mora
86th EAS Congress 2018
Genetic regulation of HDL cholesterol levels during sepsis
Liam Brunham
86th EAS Congress 2018
Genes can hurt you to develop CVD beyond classical risk factors
Stefano Romeo
86th EAS Congress 2018
Food4me – the experience
Michael Gibney
86th EAS Congress 2018
Effects of the different dietary fatty acids on health – focus on PUFA n-6. New evidences and controversies
Andrea Poli
86th EAS Congress 2018
Dysregulation of hepatic and lipoprotein metabolism in the atherogenic dyslipidemia
Marja-Riitta Taskinen
86th EAS Congress 2018
Dietary fat vs carbohydrates
Gabriele Riccardi
86th EAS Congress 2018
Diet and CVD the epidemiological view
Salim Yusuf
86th EAS Congress 2018
Development of antisense drug targeting PCSK9
Mariko Harada-Shiba
86th EAS Congress 2018
Defective Inflammation Resolution in Atherosclerosis – Mechanisms and Therapeutic Opportunities
Ira Tabas
86th EAS Congress 2018
Combination therapy – When and how
Michel Farnier
86th EAS Congress 2018
Atherothrombosis; from pathogenesis to treatment
Steffen Massberg
86th EAS Congress 2018
Are we ready to test the Lp(a) Hypothesis?
Sotirios Tsimikas
86th EAS Congress 2018
Apo B containing lipoproteins a better target for CV risk reduction?
Brian Ference
86th EAS Congress 2018
Anti-Inflammatory Therapy for Atherosclerosis – Theory and Practice
Peter Libby
86th EAS Congress 2018
A plasma circulating MIRNAS profile predicts Type 2 Diabetes MELLITUS and Prediabetes – From the cordioprev study
Antonio Camargo
86th EAS Congress 2018
A contemporary approach to dyslipidaemias, PCSK9 inhibition
Ulf Landmesser
86th EAS Congress 2018
Why TG-rich lipoproteins-non-HDL-Cholesterol matter when assessing CVD risk? – Introduction
Kausik Ray
85th EAS Congress 2017
Why TG-rich lipoproteins-non-HDL-Cholesterol matter when assessing CVD risk? – Discussion
Faculty Presenter(s)
85th EAS Congress 2017
Using naturally randomized genetic evidence to understand heritability of coronary artery disease?
Brian Ference
85th EAS Congress 2017
Updates on the guidelines. Which role for nutraceuticals?
Emilio Ros
85th EAS Congress 2017
Typical clinical cases – who may benefit?
Eric Bruckert
85th EAS Congress 2017
The value of generic medicines
Gianni Corrao
85th EAS Congress 2017
The new EAS-ESC Guidelines on diet and lifestyle in cardiovascular prevention
Gabriele Riccardi
85th EAS Congress 2017
The clinical evidence – Meta-analysis of the RCT
Matteo Pirro
85th EAS Congress 2017
The case for immune cells – An expanded cardiovascular continuum
Peter Libby
85th EAS Congress 2017
Temporal versus one-time biomarker measurements
Lars Lind
85th EAS Congress 2017
Summary and introduction of guidelines
Alberico L. Catapano
85th EAS Congress 2017
Secondary prevention
Renata Cifkova
85th EAS Congress 2017
Role of non-coding RNA for cholesterol homeostasis and atherogenesis
Kathryn Moore
85th EAS Congress 2017
Regulation of lipid mobilization and lipoprotein secretion by the intestine
Gary Lewis
85th EAS Congress 2017
Progress in understanding the role of nutrition in prevention of atherosclerosis – Discussion
Faculty Presenter(s)
85th EAS Congress 2017
Progress in understanding the role of nutrition in prevention of atherosclerosis – Chair
Jan Borén
85th EAS Congress 2017
Prognostics in patients with manifest (acute or chronic) CHD
Thomas Luscher
85th EAS Congress 2017
Primary prevention
Guy De Baker
85th EAS Congress 2017
PET-MRI
Marc Dweck
85th EAS Congress 2017
Nordic and Mediterranean diet patterns from the CVD point of view
Ursula Schwab
85th EAS Congress 2017
Microbiome and cardiometabolic disease
Fredrik Bäckhed
85th EAS Congress 2017
Mechanistic insights into innovative therapeutics in lipid lowering in vivo
Henry Ginsberg
85th EAS Congress 2017
Lysosomal acid lipase deficiency – an underdiagnosed and misdiagnosed cause of dyslipidemia and liver dysfunction
Maurizio Averna
85th EAS Congress 2017
Lowering LDL-C for cardiovascular disease
Chris Packard
85th EAS Congress 2017
Life time exposure to LDL-cholesterol is it the key to CVD risk?
Brian Ference
85th EAS Congress 2017
LDL is causal to atherosclerosis
John Chapman
85th EAS Congress 2017
Large-scale epidemiology assessment of the main determinants of cardiovascular disease
Sarah Lewington
85th EAS Congress 2017
LAL deficiency – Discussion
Faculty Presenter(s)
85th EAS Congress 2017
Introduction to Detecting plaque burden or vulnerable plaque – Which way should we go?
Lale Tokgözoğlu
85th EAS Congress 2017
Introduction to Anitschkow prize winner
Lale Tokgözoğlu
85th EAS Congress 2017
Innate immune response drives atherosclerosis
Mihai Netea
85th EAS Congress 2017
Importance of physical activity in metabolic and cardiovascular health and the influence of obesity and diabetes
Patrick Schrauwen
85th EAS Congress 2017
Hypertriglyceridaemia – ApoC-III and ANGPTL3
Sotirios Tsimikas
85th EAS Congress 2017
How to treat diabetic dyslipidaemia – Introduction
Borge Nordestgaard
85th EAS Congress 2017
How to treat diabetic dyslipidaemia
Alberto Zambon
85th EAS Congress 2017
How to treat diabetic dyslipidaemia
Gerald Watts
85th EAS Congress 2017
How LDL causes inflammation in the artery wall
Göran Hansson
85th EAS Congress 2017
Hepatic lipid and lipoprotein metabolism
Marja-Riitta Taskinen
85th EAS Congress 2017
HDL-cholesterol and cardiovascular disease – rethinking our approach
John Chapman
85th EAS Congress 2017
FOURIER – first outcomes data with a PCSK9 inhibitor
Terje R Pedersen
85th EAS Congress 2017
Fibrates in the management of AD and CVD risk
Michal Vrablik
85th EAS Congress 2017
Familial hypercholesterolaemia
Kausik Ray
85th EAS Congress 2017
Enzymatic replacement therapy for lysosomal adic lipase deficiency in adult patients with lysosomal acid lipase deficiency
Reena Sharma
85th EAS Congress 2017
Discussion – What do FOURIER data mean for clinical practice?
Faculty Presenter(s)
85th EAS Congress 2017
Diet and cardiometabolic health
Qi Sun
85th EAS Congress 2017
Demystifying the management of hypertriglyceridemia
Anne Tybjaerg-Hansen
85th EAS Congress 2017
CVD prevention strategies – Discussion
Faculty Presenter(s)
85th EAS Congress 2017
CT angiography
Jason M Tarkin
85th EAS Congress 2017
Combination therapy a better way to treat?
Lale Tokgözoğlu
85th EAS Congress 2017
Circulating miRNA for cardiovascular death prediction
Tanja Zeller
85th EAS Congress 2017
Circadian control of metabolism
Frank A.J.L. Scheer
85th EAS Congress 2017
Chronic kidney disease
Alexandros Tselepis
85th EAS Congress 2017
Brown adipose tissue – a novel target to comBAT cardiometabolic disease
Patrick Rensen
85th EAS Congress 2017
Balancing the fat – lipid droplets and human disease
Robert Farese, Jr
85th EAS Congress 2017
Atherosclerosis regression – linking GLAGOV and FOURIER
Steve Nicholls
85th EAS Congress 2017
Atherogenic dyslipidemia (AD)
Alberto Zambon
85th EAS Congress 2017
Anitschkow Lecture – Hematopoiesis, cholesterol and atherosclerosis
Alan Tall
85th EAS Congress 2017
3D ultrasound
Steve Nicholls
85th EAS Congress 2017
How genes control cholesterol
Michael S Brown
84th EAS Congress 2016
Anitschkow Lecture
John J. Kastelein
82nd EAS Congress 2014
The Anitschkow lecture
Peter Libby
81st EAS Congress 2013
A brief history of cholesterol lowering
Terje R Pedersen
Overview of the role of lipids in atherosclerosis
Petri Kovanen
2019 Intro to Clinical Lipidology
Genetic disorders of lipid metabolism with special focus on familial hypercholesterolaemia
Kees Hovingh
2019 Intro to Clinical Lipidology
An Introduction to Clinical Lipidology
Lale Tokgözoğlu
2019 Intro to Clinical Lipidology
The approach of high – and very high risk patients in the new guidelines
Lale Tokgözoğlu
2019 ESC-EAS Dyslipidaemia Guidelines
New recommendations and concepts in the new guidelines
Alberico L. Catapano
2019 ESC-EAS Dyslipidaemia Guidelines
Management of dyslipidaemias in different clinical settings
Olov Wiklund
2019 ESC-EAS Dyslipidaemia Guidelines
Important aspects related to diet and lifestyle in the new guidelines
Gabriele Riccardi
2019 ESC-EAS Dyslipidaemia Guidelines
Dyslipidaemia treatment in ACS
Lale Tokgözoğlu
2019 ESC-EAS Dyslipidaemia Guidelines
Cardiovascular risk assessment and lipid lowering for patients with DM – what do the guidelines say?
Kausik Ray
2019 ESC-EAS Dyslipidaemia Guidelines
A deep dive into EAS-ESC guidelines for dyslipidaemias
Alberico L. Catapano
ANGPTL 3 what we have learned from genetics?
Arca Marcello
88th EAS Congress 2020
Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force
April 13, 2021 | Consensus paper, Publications
Taking action: European Atherosclerosis Society targets the United Nations Sustainable Development Goals 2030 agenda to fight atherosclerotic cardiovascular disease in Europe
February 16, 2021 | Consensus paper, Publications
Therapeutic Approaches – The NLA Way
Christie Ballantyne
Therapeutic Approaches – The EAS way
Alberico L. Catapano
Targets and goals – The NLA way
Carl E. Orringer
Targets and goals – The EAS way
Chris Packard
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
February 13, 2020 | Consensus paper, Publications
Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM
January 9, 2020 | Consensus paper, Publications
The Clinician’s Handbook: Case-based advice for clinicians on the role of lipids and lipoproteins in atherosclerosis and cardiovascular disease
January 1, 2020 | Publications, Handbook
Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement
September 30, 2019 | Consensus paper, Publications
2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk
August 31, 2019 | Guideline, Publications
Overview of the current status of familial hypercholesterolaemia care in over 60 countries – The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
October 1, 2018 | Publications
Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM
July 1, 2018 |
Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract
April 27, 2018 | Consensus paper, Publications
2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia
October 16, 2017 | Publications
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
April 24, 2017 | Consensus paper, Publications
Pooling and expanding registries of familial hypercholesterolaemia toassess gaps in care and improve disease management and outcomes:Rationale and design of the global EAS Familial HypercholesterolaemiaStudies Collaboration
December 1, 2016 | Publications
European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk
October 27, 2016 | Consensus paper, Publications
Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine
April 26, 2016 | Consensus paper, Publications
Familial hypercholesterolaemia: A global call to arms
September 18, 2015 | Publications
Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment
May 25, 2015 | Publications
Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management
February 18, 2015 | Consensus paper, Publications
Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society
August 21, 2014 | Consensus paper, Publications
The Polygenic Nature of Hypertriglyceridaemia: Implications for Definition, Diagnosis and Management
December 23, 2013 | Consensus paper, Publications
Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease
November 23, 2013 | Consensus paper, Publications